AVIR Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Atea Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.16 |
| 52 Week High | US$4.60 |
| 52 Week Low | US$2.77 |
| Beta | 0.17 |
| 11 Month Change | -11.98% |
| 3 Month Change | -16.40% |
| 1 Year Change | 12.86% |
| 33 Year Change | -58.85% |
| 5 Year Change | n/a |
| Change since IPO | -89.58% |
Recent News & Updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30
Shareholder Returns
| AVIR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.7% | -5.3% | -1.2% |
| 1Y | 12.9% | 8.7% | 30.4% |
Return vs Industry: AVIR exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: AVIR underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| AVIR volatility | |
|---|---|
| AVIR Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVIR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AVIR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 75 | Jean-Pierre Sommadossi | ateapharma.com |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19.
Atea Pharmaceuticals, Inc. Fundamentals Summary
| AVIR fundamental statistics | |
|---|---|
| Market cap | US$265.21m |
| Earnings (TTM) | -US$174.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs AVIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVIR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$78.28m |
| Gross Profit | -US$78.28m |
| Other Expenses | US$95.73m |
| Earnings | -US$174.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AVIR perform over the long term?
See historical performance and comparison